ATEC analysts slash targets after earnings

Alphatec Holdings reported earnings on May 5 and walked into a wall of target-price cuts — the stock climbed 9.4% on the week despite the downgrades, creating one of the more striking bull-bear tensions in the med-tech space right now.

Options traders have turned sharply bullish, and it happened fast. The put/call ratio has collapsed to 0.42, more than a full standard deviation below its 20-day average of 0.70. That compares with readings near the 52-week high of 0.99 through most of April — when the ratio was running almost at par for weeks before the earnings release, signalling heavy hedging. The post-print unwind is dramatic. Call volume now dominates, with the PCR near its 52-week low of 0.08, suggesting the market read the earnings as a clearing event rather than a new threat.

Short positioning tells a more cautious story. SI runs at roughly 9.5% of the free float — a meaningful level for a med-tech name — but it has edged down about 5.6% over the past month from a peak near 10.2% in late March. The borrow market remains relaxed: cost to borrow sits just above 0.5% and availability is wide at roughly 680% of current short interest, meaning there is no squeeze pressure in the lending pool. The ORTEX short score of 57.2 is mid-range and has been broadly stable over recent weeks, consistent with a position that is neither building aggressively nor unwinding in bulk.

The Street maintained its buy-side conviction but slashed price targets in response to the print. TD Cowen cut its target from $20 to $11 on Wednesday — the sharpest reduction — while Piper Sandler and Needham both trimmed from $25 to $14, each keeping Overweight and Buy ratings intact. The result is a mean target near $18 against a stock trading at $10.23, implying roughly 76% upside on paper, though the gap between current price and consensus target reflects how aggressively expectations have been reset. The bull case rests on surgical volume growth — management cited a 24% rise — and the OsteoAdapt biologics distribution deal expanding the spinal portfolio. Bears point to the long road to the $1 billion revenue target and margin pressure from rising operating costs, with estimated revenue for the year near $882 million and a GAAP net loss still running around $79 million.

Insider activity is worth noting, though the tone is one-sided. The 90-day net position shows insiders net selling roughly $14.6 million in aggregate. The COO sold over 260,000 shares at $12.30 in mid-March, the CEO sold around 220,000 shares at $12.57 the same month, and the CFO sold near 149,000 shares across two tranches. All trades occurred with the stock between $12 and $13 — well above the current $10.23 price. None of the recent filings show any buying to counterbalance the distribution.

Among correlated peers, SI-BONE gained 9.6% on the week — essentially matching ATEC's move — while iRhythm fell 5.8% and Merit Medical dropped 9.4%, suggesting the week's gains for ATEC and SIBN were more idiosyncratic than a broad med-tech rally. The next data points to watch are any revised guidance commentary from management and whether the target-cut wave draws incremental short interest back toward the mid-March highs, or whether the options market's post-earnings bullishness proves durable.